Here Are Some Essential Facts About Medical Properties Trust (MPW)

Shares of Large-cap real estate company Medical Properties Trust moved 14.7 this evening, and are now trading at $4.68 per share. On the other hand, the average analyst target price for the stock is $7.5.

Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities.

Medical Properties Trust Investors Should Consider This:

  • Medical Properties Trust has moved -61.0% over the last year.

  • The company has a price to earnings growth (PEG) ratio of -1.22. A number between 0 and 1 could mean that the market is undervaluing Medical Properties Trust's estimated growth potential

  • Its Price to Book (P/B) ratio is 0.34

  • Medical Properties Trust currently returns an annual dividend yield of 25.0%.

Understanding Medical Properties Trust's Operating Margins

Date Reported Total Revenue ($ k) Operating Expenses ($ k) Operating Margins (%) YoY Growth (%)
2023 1,420,431 1,199,127 -3 -104.84
2022 1,542,851 898,204 62 31.91
2021 1,544,669 873,378 47 27.03
2020 1,249,238 749,526 37 -15.91
2019 854,197 510,546 44 -66.15
2018 784,522 446,597 130

Over the last 4 years, Medical Properties Trust's operating margins have averaged 52.8%, which is better than the 25.46% Specialty Real Estate Investment Trust industry average. We also note that the company's operating margins have a high coefficient of variability at 112.4%. However the firm's margins are declining at a compounded yearly rate of -47.9%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.